Effect of ESAT-6 on human T cell Function
Effect of ESAT-6 on human T cell Function
批准号:
7640305
负责人:
Buka Samten
金额:
$20.13万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-05 至 2011-05-31
关键词:
AbbreviationsAntigensApoptosisBacteriaBindingBiological AssayCattleCause of DeathCaviaCell Membrane ProteinsCell physiologyCellular ImmunityCyclic AMP-Responsive DNA-Binding ProteinCytolysisDataDevelopmentEMSAElectrophoretic Mobility Shift AssayEnzyme-Linked Immunosorbent AssayEnzymesFigs - dietaryGoalsGoldHealthHumanImmune responseImmune systemImmunityImmunoassayImmunoprecipitationInterferonsInterleukin-10LifeLigandsLinkMAP Kinase GeneMacrophage ActivationMammalian CellMass Spectrum AnalysisMediatingMitogen-Activated Protein KinasesMolecularMolecular TargetMononuclearMusMycobacterium tuberculosisPeripheral Blood Mononuclear CellPhagocytesPhosphotransferasesPlayProductionProteinsPublic HealthRoleSignal PathwaySignal TransductionSignaling MoleculeSmall Interfering RNASurface Plasmon ResonanceT-Cell ActivationT-Cell ProliferationT-Cell ReceptorT-LymphocyteTissuesTransforming Growth FactorsTuberculosisVaccine AntigenVaccinesVirulenceWestern Blottingactivating transcription factorchromatin immunoprecipitationcytotoxicitydisorder controlimmune functionimmunogenicimprovedinsightmycobacterialneutralizing antibodynonhuman primatepromoterpublic health prioritiespublic health relevanceresearch studyresponsetooltranscription factortreatment strategyvaccination strategyvaccine candidatevaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tuberculosis remains a major global health problem and vaccine development is a critical priority. T-cells play a pivotal role in protection against Mycobacterium tuberculosis. However, M. tuberculosis is known to inhibit human immunity, but the mechanisms are not well understood. Early secreted antigenic target of 6 kD (ESAT-6) is an immunogenic protein that is a potential vaccine candidate, but also contributes to virulence and cytolysis of mammalian cells. Our preliminary data indicate that ESAT-6 directly inhibits human T cell proliferation and IFN-g secretion, and these effects are not due to cytotoxicity or increased apoptosis. Our goal is to understand the molecular mechanisms by which ESAT-6 inhibits human T cell IFN-g production. The specific aims are: 1. Identify the signaling pathways by which ESAT-6 inhibits T cell IFN-g production. We will determine the effect of ESAT-6 on transcription factors that bind to the IFN-g proximal promoter, using promoter pull-down assays and chromatin immunoprecipitation (aim 1.1). We will evaluate the effect of ESAT-6 on molecules that mediate signaling through the T-cell receptor (aim 1.2) and on the intermediary signaling molecules, mitogen-activated protein kinases (aim 1.3), using immunoprecipitation, Western blotting and functional kinase assays 2. Identify a mammalian ligand for ESAT-6 on human T-cells. We will use biotinylated ESAT-6 to pull down proteins from extracts of purified T-cells, elute the proteins, separate them by SDS-PAGE and identify them by mass spectrometry (aim 2.1). The putative ligand will be cloned and expressed, and interactions between ESAT-6 and its ligand will be confirmed by surface plasmon resonance and protein overlay assays (aim 2.2). To determine the functional significance of the interaction between ESAT-6 and its putative ligand, we will determine if neutralizing antibodies and/or siRNA to the ESAT-6 ligand abrogate the inhibitory effects of ESAT-6 on T-cells (aim 2.3). PUBLIC HEALTH RELEVANCE: Tuberculosis remains a tremendous public health problem world-wide, and an effective vaccine would contribute greatly to disease control. Early secreted antigenic target of 6 kD (ESAT-6) is a Mycobacterium tuberculosis protein that is a promising vaccine candidate, but also contributes to virulence and tissue damage. This proposal seeks to understand the mechanisms by which ESAT-6 inhibits human T-cell immune function, information that is critical for development of improved vaccines and treatment strategies for tuberculosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Suppression of Allograft Rejection by A Novel Protein ESAT-6
-
批准号:8427281
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2012
-
负责人:Buka Samten
-
依托单位:
ESAT-6 primes dendritic cells with reduced IL-12 and increased IL-23 production
-
批准号:8282486
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2012
-
负责人:Buka Samten
-
依托单位:
Suppression of Allograft Rejection by A Novel Protein ESAT-6
-
批准号:8224077
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2012
-
负责人:Buka Samten
-
依托单位:
ESAT-6 primes dendritic cells with reduced IL-12 and increased IL-23 production
-
批准号:8448065
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2012
-
负责人:Buka Samten
-
依托单位:
Effect of ESAT-6 on human T cell Function
-
批准号:7860399
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2009
-
负责人:Buka Samten
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: